Payment overview · 2025
General Payments
$763.01
20 reported records · 12 companies
Healthcare provider profile · identity verified
Michael Glenn Winnie, MD
Allopathic & Osteopathic Physicians|Family Medicine · CORPUS CHRISTI, TX · NPI 1821196932
Verified facts
What the public records show
CMS Open Payments records show Michael Glenn Winnie, MD received $763.01 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.84 | 21.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.52 | 18.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.84 | 16.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.23 | 10.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $64.98 | 8.5% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$58.82 | 7.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.21 | 4.2% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $24.53 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.25 | 3.2% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $23.55 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.12 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.12 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $763.01 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $162.84 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.23 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $64.98 | 4 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $58.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.85 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 544 | 111 |
| Trazodone Hcl | Trazodone Hcl | 517 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 79 |
| Furosemide | Furosemide | 390 | 80 |
| Gabapentin | Gabapentin | 384 | 71 |
| Lisinopril | Lisinopril | 360 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 251 | 47 |
| Donepezil Hcl | Donepezil Hcl | 247 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 45 |
| Famotidine | Famotidine | 225 | 48 |
| Losartan Potassium | Losartan Potassium | 225 | 57 |
| Metformin Hcl | Metformin Hcl | 222 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 49 |
| Potassium Chloride | Potassium Chloride | 211 | 47 |
| Divalproex Sodium | Divalproex Sodium | 206 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 202 | 32 |
| Eliquis | Apixaban | 194 | 33 |
| Sertraline Hcl | Sertraline Hcl | 191 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 180 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 36 |
| Memantine Hcl | Memantine Hcl | 176 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 47 |
| Levetiracetam | Levetiracetam | 142 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 29 |
| Alprazolam | Alprazolam | 132 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 25 |
| Lactulose | Lactulose | 125 | 23 |
| Montelukast Sodium | Montelukast Sodium | 115 | 28 |
| Mirtazapine | Mirtazapine | 113 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 22 |
| Lorazepam | Lorazepam | 108 | 25 |
| Tramadol Hcl | Tramadol Hcl | 107 | 32 |
| Omeprazole | Omeprazole | 104 | 25 |
| Azithromycin | Azithromycin | 103 | 78 |
| Carvedilol | Carvedilol | 101 | 20 |
| Buspirone Hcl | Buspirone Hcl | 97 | 17 |
| Latanoprost | Latanoprost | 94 | 13 |
| Simvastatin | Simvastatin | 94 | 19 |
| Meloxicam | Meloxicam | 93 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 14 |
| Jardiance | Empagliflozin | 80 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 14 |
| Prednisone | Prednisone | 79 | 49 |
| Pregabalin | Pregabalin | 77 | 15 |
| Finasteride | Finasteride | 74 | 14 |
| Ezetimibe | Ezetimibe | 72 | 15 |
| Methocarbamol | Methocarbamol | 72 | 29 |
| Temazepam | Temazepam | 71 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 53 |
| Myrbetriq | Mirabegron | 67 | 14 |
| Risperidone | Risperidone | 67 | 12 |
| Mounjaro | Tirzepatide | 65 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 30 |
| Midodrine Hcl | Midodrine Hcl | 63 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 14 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Celecoxib | Celecoxib | 60 | 17 |
| Trulicity | Dulaglutide | 59 | suppressed |
| Spironolactone | Spironolactone | 58 | 17 |
| Baclofen | Baclofen | 57 | 12 |
| Farxiga | Dapagliflozin Propanediol | 56 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 12 |
| Vascepa | Icosapent Ethyl | 55 | suppressed |
| Rivastigmine | Rivastigmine | 53 | suppressed |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Clonazepam | Clonazepam | 49 | 12 |
| Metformin Hcl Er | Metformin Hcl | 48 | 15 |
| Allopurinol | Allopurinol | 47 | 12 |
| Valacyclovir | Valacyclovir Hcl | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Digoxin | Digoxin | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 11 |
| Linzess | Linaclotide | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Clonidine Hcl | Clonidine Hcl | 41 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Glipizide | Glipizide | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 26 |
| Memantine Hcl Er | Memantine Hcl | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 11 |
| Multaq | Dronedarone Hcl | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 32 |
| Ondansetron Odt | Ondansetron | 35 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Fanapt | Iloperidone | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 11 |
| Simbrinza | Brinzolamide/Brimonidine Tart | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 15 |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Nystatin | Nystatin | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Hydrocodone Bitartrate Er | Hydrocodone Bitartrate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $763.01 · 20 records | AstraZeneca Pharmaceuticals LP | AFREZZA, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, FARXIGA, NURTEC ODT, Ozempic, Quviviq, REXULTI, Rybelsus, SYMPLICITY G3, XIFAXAN, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error